Current Report Filing (8-k)
13 April 2020 - 3:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 13, 2020
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
N|A
|
|
N|A
|
|
N|A
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 13, 2020, Arch Therapeutics, Inc. (the “Company”)
issued a press release announcing the Company’s receipt of a CE (Conformité
Européenne) mark for its first-in-class wound care product, AC5TM Topical Hemostat (“AC5”).
Under applicable European Union (“EU”) medical
device directives, a CE mark is a symbol placed on a product that declares that the product is compliant with the essential requirements
of applicable EU health, safety and environmental protection legislation. In order to receive a CE mark for a product candidate,
the company producing the product candidate must select a country in which to apply. Each country in the EU has one competent authority
(“CA”) that implements the national regulations by interpreting the EU directives. CAs also designate and regulate
Notified Bodies. An assessment by a Notified Body in the selected country within the EU is required in order to commercially distribute
the device. In addition, compliance with ISO 13485 issued by the International Organization for Standardization, among other standards,
establishes the presumption of conformity with the essential requirements for CE marking. Certification to the ISO 13485 standard
demonstrates the presence of a quality management system that can be used by a manufacturer for design and development, production,
installation and servicing of medical devices and the design, development and provision of related services.
Devices that comply with the requirements of the laws of the
selected member state applying the applicable EU directive are entitled to bear a CE mark and can be distributed throughout the
member states of the EU, as well as in other countries that have mutual recognition agreements with the EU or have adopted the
EU’s regulatory standards.
The CE mark provides authorization to commercialize AC5 in Europe
as a dressing and to control bleeding in external skin wounds in both out- and in-patient settings.
The text of the press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is
incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following exhibits are being filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
Dated: April 13, 2020
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name: Terrence W. Norchi, M.D.
|
|
|
Title: President, Chief Executive Officer
|
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Arch Therapeutics, Inc. News-Artikel